Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
Pfizer CEO Albert Bourla suggested that fully vaccinated people would need their third vaccine dose, maybe 12 months after they got their second - the EU is currently in talks to secure a further 1.8 billion doses.
Researchers in the UK started a clinical trial on mixing vaccines in February - today (14 April) a new study will look into mixing Moderna and Novavax doses.
US authorities paused the use of the Johnson & Johnson single dose vaccine as they look into six cases of blood clots that developed in women aged between 18 and 48.
Uninfected people lived with one infected individual as part of the study - the COVID antibody drug gave them 72% protection against catching the virus themselves.
Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.
Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.
EU leaders today (25 March) decided not to create an export ban for AstraZeneca vaccines made for the UK - but the feud between AstraZeneca and the bloc remains close to the surface of future discussions.
In a study of over 32,000 people, a US trial found the AstraZeneca vaccine was 100% effective against deaths caused by COVID-19 - the vaccine did not show any connection to blood clots.
Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.
The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".
Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.
